Biology of Blood and Marrow Transplantation
Volume 14, Issue 1 , Pages 7-9 , January 2008

Alemtuzumab-Induced Resolution of Refractory Cutaneous Chronic Graft-Versus-Host Disease

  • Guillermo J. Ruiz-Argüelles

      Affiliations

    • Centro de Hematología y Medicina Interna de Puebla, Puebla, Mexico
    • Corresponding Author InformationCorrespondence and reprint requests: Guillermo J. Ruiz-Argüelles, MD, FACP, FRCP (Glasg), Centro de Hematología y Medicina Interna de Puebla, 8B Sur 3710, 72530 Puebla, Mexico.
    • ,
  • Javier Gil-Beristain

      Affiliations

    • Centro Médico Anzures, Puebla, Mexico
    • ,
  • Mario Magaña

      Affiliations

    • Centro de Dermatología & Dermatopatología, Mexico City, Mexico
    • ,
  • Guillermo J. Ruiz-Delgado

      Affiliations

    • Hospital Universitario de Monterrey, Mexico City, Mexico

References 

  1. Fraser SJ, Baker KS. The management and outcome of chronic graft-versus-host disease. Brit J Haematol. 2007;138:131–135
  2. Ferarra JL. Novel strategies for the treatment and diagnosis of graft versus host disease. Best Pract Res Clin Haematol. 2007;20:91–97
  3. Johnson ML, Farmer ER. Graft-versus-host reactions in dermatology. J Am Acad Dermatol. 1998;38:369–392
  4. Hymes SR, Turner ML, Champlin RE, et al. Cutaneous manifestations of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2006;12:1101–1113
  5. Giralt S. The role of alemtuzumab in nonmyeloablative hematopoietic transplantation. Sem Oncol. 2006;33(Suppl 5):S36–S43
  6. Khouri IF, Albitar M, Saliba RM, et al. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decrease incidence of acute graft-versus-host disease with unique pharmacokinetics. Bone Marrow Transplant. 2004;33:833–837
  7. Busca A, Locatelli F, Lovisone E, et al. Treatment of severe refractory acute graft-versus-host disease of the gastrointestinal tract with Campath 1H. Biol Blood Marrow Transplant. 2005;11:734–736
  8. Carella AM, Beltrami G, Scalzulli PR, et al. Alemtuzumab can successfully treat steroid-refractory acute graft versus host disease (aGVHD). Bone Marrow Transplant. 2004;33:131–132
  9. Wandroo F, Auguston B, Cook M, et al. Successful use of Campath-1H in the treatment of steroid refractory liver GVHD. Bone Marrow Transplant. 2004;34:285–287
  10. Varadi G, Reuven OR, Slavin S, et al. In vivo Campath-1 monoclonal antibodies: a novel mode of therapy for acute graft-versus-host disease. Am J Hematol. 1996;52:236–237
  11. Schneider M. Exploring new territory: considering the future. Lupus. 2007;16:221–226
  12. Greinix HT, Pohlreich D, Maalouf J, et al. A single-center pilot validation study of a new chronic GVHD skin scoring system. Biol Blood Marrow Transplant. 2007;13:715–723
  13. Peñas PF, Fernández-Herrera J, García-Díez A. Dermatologic treatment of cutaneous graft versus host disease. Am J Clin Dermatol. 2004;5:403–416
  14. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti C52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768–773
  15. Hale G, Rebello P, Kimby E, et al. Blood levels of alemtuzumab during treatment of patients with chronic lymphocytic leukemia: Comparison of intravenous and subcutaneous route of administration. Blood. 2002;100(Suppl 1):777
  16. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554–3561
  17. Gómez-Almaguer D, Ruiz-Argüelles GJ, González-Llano O, et al. Alemtuzumab in the treatment of steroid refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13(Suppl 2):106

PII: S1083-8791(07)00488-0

doi: 10.1016/j.bbmt.2007.09.013

Biology of Blood and Marrow Transplantation
Volume 14, Issue 1 , Pages 7-9 , January 2008

Article Tools

* Image Usage & Resolution